(Q40099238)

English

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

scientific article published on June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

B Schwarz

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

M Gouveia

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

J Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

G Nocea

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

K Jameson

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

J Cook

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

G Krishnarajah

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

E Alemao

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

D Yin

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

H Sintonen

10

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

publication date

1 June 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

10 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

43-55

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Direct medical costs of type 2 diabetes and its complications in Switzerland.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Revealing the cost of Type II diabetes in Europe.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

The importance of tight glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

The economic and quality of life impact of hypoglycemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00886.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2008.00886.X

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40099238&oldid=1885274455"